Literature DB >> 16617029

Attention deficit disorders: are we barking up the wrong tree?

Pedro Cabral1.   

Abstract

Attention deficit disorder (AAD) and attention deficit/hyperactivity disorder (ADHD) are very frequent and protean developmental disorders without a definite biologic marker. This review proposes a framework to understand the enlarged spectrum of its manifestations based on current knowledge of the mechanisms underlying arousal and attention variations during sleep/wake cycle. The neuro-modulation's pivotal role in this process as well as in the fine tuning of synaptic architecture during development must be taken into account when trying to understand the marked fuzziness of the symptoms and the very high prevalence of reported co-morbidities. The series of related interactions includes a cyclic deactivation of the dorso-lateral portion of the prefrontal cortex (DLPFC) during sleep, suspending executive functions, co-occurring with rhythmic periods of decreased noradrenergic tonus. A protracted unbalance in modulation, with catecholaminergic relative deficiency, could explain less-than-optimum waking DLPFC activation and the most important manifestations of ADD. Beside the well documented dopaminergic effects of stimulant medication used in ADD and ADHD, a more important role must be assigned to noradrenaline (NA). At this light hyperactivity and impulsivity are less important dimensions. Rather, an attention deficit spectrum disorder should probably be regarded as a complication of a core defect in prefrontal cortex dependent inhibitory control, underlying inattention.

Entities:  

Mesh:

Year:  2006        PMID: 16617029     DOI: 10.1016/j.ejpn.2006.02.004

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  2 in total

1.  General versus executive cognitive ability in pupils with ADHD and with milder attention problems.

Authors:  Ulla Ek; Joakim Westerlund; Elisabeth Fernell
Journal:  Neuropsychiatr Dis Treat       Date:  2013-01-29       Impact factor: 2.570

2.  Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine.

Authors:  Alain Joseph; Martin Cloutier; Annie Guérin; Roy Nitulescu; Vanja Sikirica
Journal:  Patient Prefer Adherence       Date:  2016-03-24       Impact factor: 2.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.